Post TAVI Hypertension is a predictor of better evolution

Original title: Post-Procedural Hypertension Following Transcatheter Aortic Valve Implantation Incidence and Clinical Significance. Reference: Gidon Y. Perlman et al. J Am Coll Cardiol Intv 2013. Article in press.

Pre-procedural hypertension (HTN) is a risk factor and a predictor of increased mortality after surgical aortic valve replacement (AVR). The disappearance of the pressure gradient across the aortic valve following surgical AVR often leads to dramatic hemodynamic changes and increased hypotension. This study prospectively looks into hemodynamic changes after transcatheter aortic valve implantation (TAVI) and its clinical implications at 12 months follow up. Patients were divided into 2 groups, according to the presence or the increase of blood pressure after TAVI. Increased BP after TAVI was defined as sustained systolic pressure >140 mm Hg or diastolic pressure >90 mm Hg that was not present at baseline, before TAVI; the need to double the dosage of an antihypertensive drug; the need to add an additional drug to the pre-procedural scheme.

Outcomes were assessed at 30 days and 12 months; all cause death, infarction, stroke, heart failure and recurrent hospitalization were considered adverse events. 105 consecutive patients were included. Overall, systolic BP increased immediately after TAVI in the entire cohort by an average of 15 ± 31 mm Hg., which still remained 8 mmHg above baseline at 5 days after procedure, despite treatment (p<0.01 for both), diastolic pressure, on the other hand, saw a significant reduction. 53 patients out of 105 (51%) fulfilled on of the criteria for increased BP above mentioned, which required intensified treatment or even antihypertensive drugs, temporarily.

Baseline characteristics were similar in both groups, with the exception of BMI (Body mass index) and number of drugs to reach similar BP at baseline, before TAVI. Cardiac output, cardiac index, and stroke volume after TAVI were significantly increased in patients with increased BP versus patients with stable BP (p < 0.05). The rates of in-hospital, 30 day, and 12-month serious adverse events were 21%, 30%, and 53%, respectively, for patients with increased BP as compared to 60%, 71%, and 83% for patients with stable BP (p < 0.01 for all differences between groups). Most of these events were episodes of worsening heart failure and there were no differences in mortality rate. The rates of procedure-related complications with possible hemodynamic consequences including bleeding, vascular complications, pacemaker implantation, and aortic insufficiency did not differ significantly between the groups.

Conclusion: 

Around 50% of post TAVI patients present a significant increase of systolic BP, requiring immediate and prolonged treatment. So far, this has been the first study to show that this phenomenon predicts a better evolution of heart function and an even better short and midterm evolution.

Editorial Comment: 

The rise in BP may represent myocardial contractile reserve, already similarly described in dobutamine stress echocardiography and aortic stenosis studies. The rise in BP may represent a lack of adverse events such as vascular injury and bleeding. However, there were no significant differences in the rates of procedural complications between the two groups.

SOLACI.ORG

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...